alexa Wnt/FZD Genetics in Glioblastoma | Open Access Journals
ISSN: 2161-1041
Hereditary Genetics: Current Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Wnt/FZD Genetics in Glioblastoma

Sergio Casas-Tintó*

Instituto Cajal, CSIC, Madrid, Spain

*Corresponding Author:
Casas-Tintó S
Instituto Cajal, CSIC, Madrid, Spain
Tel: 91 585 4750
E-mail: [email protected]

Received Date: July 10 2017 Accepted Date: July 31, 2017 Published Date: August 07, 2017

Citation: Casas-Tintó S (2017) Wnt/FZD Genetics in Glioblastoma. Hereditary Genet 6: 186. doi:10.4172/2161-1041.1000186

Copyright: © 2017 Casas-Tintó S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Hereditary Genetics: Current Research

Introduction

Wnt/FZD signalling pathway regulates proliferation, migration, cell fate and death. Deregulation of this pathway is one of the hallmarks for glioblastoma (GBM), the most malignant brain tumour. Wnt/FZD aberrant signalling promotes glioma cell proliferation, propagation and resistance to conventional chemo and radiotherapy. Current research efforts to understand the signalling deregulation by Wnt/FZD focus on the design of Wnt inhibitors and on the characterization of downstream effectors. However, little is known about the origin of this deregulation. To date, there is no evidence for gain of expression of Wnt or its receptors even though downstream effectors are clearly upregulated in GBM. Among the novel alternatives we discuss here the downregulation of Wnt antagonists and the deregulation of vesicle trafficking system in GBM cells. Both strategies would lead to an oncogenic trigger towards increasing Wnt signalling.

Comment and Discussion

The origin of mutations in specific genes has been essential to decipher the cause and progression of human diseases. The primitive idea of one-gene-one protein has evolved during the last decades and, nowadays, the term genetic mutation uncovers a range of possibilities from single base pair changes in the open reading frame to epigenetic modifications of regulatory regions. The latest has emerged as a revolutionary explanation for a number pathological scenario in which no Mendelian mutations are detected in the open reading frame of the gene but gene deregulation is evident.

We have recently reviewed the contribution of Wnt to central nervous system diseases [1]. In particular, we have addressed WNT contribution in two of the most common pathologies of the CNS, Alzheimer´s disease and Glioblastoma (GBM).

In the canonical pathway, Wnt is activated upon binding to specific receptors in the plasma membrane (LRPs and FZD). Then, a cascade of events occurs in the cytoplasm of the cell which includes the inactivation of a destruction complex (APC and Axins) that releases β-catenin (armadillo in Drosophila) and its subsequent translocation into the nucleus. There, β-cat stimulates the expression of a collection of genes (i.e., Cycling D1 and Myc) that drive changes in cell proliferation and physiology.

GBM is a type of brain tumor originated in glial cells, astrocytes. It is characterized for its aggressiveness and great infiltrative nature. GMB is resistant to the standard treatments including tumor resection, radiotherapy and chemotherapy (Temozolomide). Thus, few patients survive longer than 5 years after diagnosis [2] and the average survival rate is shorter than 2 years [3].

One of the hallmarks of bad prognosis in GMB is the activation of β-cat [4], indicating an over-activation of the Wnt/FZD pathway [5]. Following that rationale, we searched in the COSMIC database (Collection of Somatic Mutations in Cancer) for gain of function mutations or copy number variations in Wnt/FZD genes. The analysis showed that mutations in Wnt or FZD are rather sporadic and do not correlate with GBM progression. These data are consistent with the lack of mutations in β-catenin in GBM patients [6].

This finding might result contradictory since the over-activation of this pathway has been well documented in several types of cancer including GBM [4]. On the other hand, it seems clear that β-catenin plays a central role in other types of human cancers [7-9]. Recent studies have focused in other components of the pathway and their contribution to cancer development. For example, APC, β-catenin, AXIN, WTX and TCF4 also contribute to the development of certain types of cancer [10,11].

Alternative strategies could account for pathway activation without up regulating Wnt or FZD. Recent studies have proposed epigenetic modifications as an intriguing alternative for regulating the activity of signalling pathways. In particular, sFRPs, Dickkopf, NKD and WIF1 are potent inhibitors of the Wnt signal transduction pathway which happen to be down regulated in GBM [12] (Figure 1). Deregulation of these proteins account for 40-50% of primary GBM cases [12,13]. Epigenetic changes including promoter hypermethylation reduce the expression of these inhibitors and, as a consequence, there is a hyperactivation of Wnt/FZD signalling. In turn, this effect yields to β-cat activation in GBM cells and contributes to tumor progression (reviewed in [14]).

hereditary-genetics-Schematic-representation

Figure 1: Schematic representation of a GBM cell. Wnt/FZD signaling regulates β-catenin translocation into the nuclei to promote gene expression. Pathway agonists expression (sFRPs, DKK1, NKD or WIF1) is downregulated in GBM cells facilitating Wnt signaling. FZD receptor is internalized and then either recycled or sent to degradation, the equilibrium of this endosomal system is altered in GBM cells and can mediate Wnt signaling through FZD stability.

Likely, however, the number of strategies to activate WNT pathway in GBM cells is still incomplete. Among the additional possibilities to account for the WNT pathway activation in the absence of genomic mutations or epigenetic modifications, cellular mechanisms favouring oncogenic signalling have been proposed recently for GBM. In particular, endosomal trafficking which mediates receptor internalization, signalling, recycling and proteolysis is deregulated in GBM.

Wnt/FZD and Epidermal Growth Factor Receptor (EGFR) pathways are pivotal in GBM progression and interactions between these signals are well documented [15]. Vesicle trafficking regulates Receptor Tyrosine Kinase (RTK) pathways such as EGFR [16] as well as others including Wnt pathway [17,18]. This novel perspective would fit with the lack of receptor expression upregulation but, with an increase in β-catenin activity (Figure 1). The validation of this approach is currently under study, endosomal trafficking needs to be established as a primary or secondary cause of oncogenesis in GBM.

Conclusion

The genetic heterogeneity and rapid transformation of GBM cells grants resistance to current therapeutical treatments. There is a need to design novel strategies against oncogenic signals in GBM which cannot rely on founder mutations. Cellular characteristics such as receptor recycling if shared by GBM cells, are not necessarily genetic mutations. These tumor features emerge as objects of study and the genes implicated might be of interest for future therapies. Wnt/FDZ pathway is critical for tumoral growth and has appeared as a novel feature in GBM. Despite the lack of genetic mutations driving Wnt/FZD overexpression, downstream targets upregulation is a hallmark in patients. We discuss other possibilities besides genetic mutations in oncogenes as a strategy to increase Wnt pathway signaling. Downregulation of Wnt antagonists or over activation of the endosomal recycling system may possibly increase Wnt signaling and promote oncogenic growth in GBM cells.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 140
  • [From(publication date):
    August-2017 - Nov 21, 2017]
  • Breakdown by view type
  • HTML page views : 116
  • PDF downloads : 24
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords